催乳素瘤治疗模式的转变——100例连续神经外科手术病例的前瞻性系列研究
本研究前瞻性纳入2021年1月至2023年8月在本中心接受手术的100例连续催乳素瘤患者,评估术前评估、手术结局及健康相关生活质量。手术目标(减瘤/全切)在90%患者中达成,长期并发症发生率为4%;78例择期全切患者缓解率91%,术前估计高概率首次全切者(n=52)和再次手术者(n=9)缓解率分别为92%和89%。术后生活质量评分显著改善。
要点
- 100例连续手术催乳素瘤患者中,多巴胺激动剂不耐受是最常见手术指征(n=68)。
- 择期全切患者缓解率达91%,术前估计高概率首次全切者和再次手术者缓解率分别为92%和89%。
- 术后Leiden bothers and needs垂体问卷总分及总需求评分显著改善(P<.001和P=.006)。
核心结论
- 在有经验的垂体中心,(重复)催乳素瘤手术可达到高缓解率并改善健康相关生活质量,与最新2023年指南的强调一致。
研究设计与样本
- 前瞻性队列研究,纳入2021年1月至2023年8月在本中心接受手术的100例连续催乳素瘤患者(72例女性),随访中位时间15.0个月(10.0-24.8个月)。
- 在术前、术后2周、术后6个月及随访时点收集临床数据,使用Leiden bothers and needs垂体问卷测量健康相关生活质量。
主要发现
- 多巴胺激动剂不耐受是最常见手术指征(n=68)。
- 手术目标(减瘤/全切)在90%患者中达成,长期并发症发生率为4%。
- 78例择期全切患者缓解率为91%;术前估计高概率首次全切者(n=52)和再次手术者(n=9)缓解率分别为92%和89%。
- 术后Leiden bothers and needs垂体问卷总分改善(P<.001,Δ-3.4,四分位距-14.4至-0.9),总需求评分亦改善(P=.006,Δ-1.8,四分位距-11.9至1.3)。
临床怎么用
- 本中心将择期催乳素瘤手术作为常规治疗,术前经多学科团队评估,术后按2周、6个月及随访时点进行结局评估。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To evaluate patients with prolactinoma treated surgically in a time when elective prolactinoma surgery became routine in our center, using a comprehensive outcome set, focusing on preoperative assessments, surgical outcomes, and health-related quality of life (HR-QoL). METHODS: Cohort of consecutive patients with prolactinoma undergoing surgery between January 2021 and August 2023. Clinical data were collected during multidisciplinary team meetings/from medical records at distinct timepoints: (1) presurgery, (2) 2 weeks postsurgery, (3) 6 months postsurgery, and (4) follow-up (median, 15.0 [10.0-24.8 months]). HR-QoL was measured using the Leiden Bothers and Needs Pituitary questionnaire. Data were described for all patients, and patients undergoing elective total resection, with additional subgroups of (1) patients undergoing a high-probability first total resection and (2) reoperations aiming for total resection. RESULTS: One hundred surgically treated patients with prolactinoma were included (72 female). Dopamine agonist intolerance was the most frequent indication (n = 68). The surgical goal (debulking/total resection) was achieved in 90% of patients. Long-term complications occurred in 4% of patients. Seventy-eight patients underwent an elective total resection, achieving remission in 91%. The subsets of preoperatively estimated high-probability-first total resections (n = 52) and reoperations (n = 9) achieved remission in 92% and 89%, respectively. Leiden Bothers and Needs Pituitary Total Bothers and Total Needs scores improved significantly after surgery (P < .001, Δ-3.4 [interquartile range, -14.4 to -0.9] and P = .006, Δ-1.8 [interquartile range, -11.9 to 1.3]), respectively. CONCLUSION: High remission rates were achieved, improving HR-QoL, demonstrating (repeat) prolactinoma surgery is effective in an experienced pituitary center, as highlighted in the most recent guideline (2023).
引用
- van Trigt VR, Bakker LEH, Pelsma ICM, et al. The Changing Treatment Paradigm for Prolactinoma-A Prospective Series of 100 Consecutive Neurosurgical Cases. J Clin Endocrinol Metab. 2025. PMID: 39292628. doi:10.1210/clinem/dgae652
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。